Introduction
The prostaglandins (PGs) are a family of structurally related molecules that are produced by cells in response to a variety of extrinsic stimuli and regulate cellular growth, differentiation, and homeostasis (reviewed by Smith, 1989 Smith, , 1992 
Results
PGLh and Its PGJ2 Metabolites Are PPARy Activators As part of an effort to identify natural PPAR ligands, a large number of arachidonic acid derivatives were screened in a transient transfection assay. An established chimera system was used, in which the ligand-binding domains of the three murine PPAR subtypes were fused to the DNAbinding domain of the yeast transcription factor GAL4 (Lehmann et al., 1995) . Expression plasmids for the GAL4-PPAR chimeras were transfected into CV-1 cells together with a chloramphenicol acetyltransferase (CAT) reporter construct containing five copies of the GAL4-binding site upstream of the minimal thymidine kinase (tk) promoter. As previously shown (Lehmann et al., 1995) , all three PPAR chimeraswere activated by 1 x 1 Om4 M of the peroxisome proliferator Wyl4,643 (Figure 1 ). The PPARa and PPARy chimeras were also activated in the presence of 1 x 10e5 M ETYA, and, to a lesser extent, arachidonic acid ( Figure 1) . interestingly, analysis of cyclooxygenase metabolites of arachidonic acid revealed PGD2 to be an efficacious activator of the PPARa and PPARy chimeras at a concentration of 1 x 1O-5 M (Figure 1 ). The efficacy of PGD2 in activating PPARy was comparable to that of the thiazolidinedione BRL49653, which we recently showed to be a high affinity PPARy ligand (Lehmann et al., 1995) . Little or no activation of the NUCl chimera was detected in the presence of these PGs (Figure 1) .
The potency of PGl& in the activation of the PPARa and PPARy chimeras was examined next. In dose-response analysis, the activities of the PPARa and PPARy chimeras failed to plateau at PGDZ concentrations up to 1 x 10m5 M (Figures 2A and 28 , open squares). Thus, while PGDz Cell extracts were subsequently assayed for CAT activity. (C) PGD2 metabolic pathway leading to the formation of PGJ*, A"-PGJ,, and 15-deoxy-A'*, "-PGJ2.
is an efficacious activator of the PPARs, it lacks potency in its induction of these orphan receptors. The efficacy of PGD2 in activating the PPARa and PPARy chimeras coupled with its relative lack of potency suggested that PGD2 might be metabolized in CV-1 cells to more potent PPAR activators. Indeed, PGD2 is known to be readily metabolized in vitro and in vivo to yield the J2 series of PGs ( Figure 2C ). Incubation of PGD2 in the presence of human plasma or human serum albumin results in the rapid accumulation of several major dehydration and isomerization products, including A12-PGJ2 and 15-deoxy-A", j4-PGJ2 (Fitzpatrick and Wynalda, 1983; Kikawa et al., 1984) . Ai2-PGJ2 has been shown to be asignificant PGD, metabolite present in human and monkey urine, indicating that the Jp series of PGs also form in vivo (Hirata et al., 1988) .
In cotransfection assays, the three J-ring PGs were efficacious activators of both the PPARa and PPARy chimeras (Figures 2A and 2B) . Interestingly, 15-deoxy-A12, 14-PGJ2 was significantly more potent than its precursors in the activation of the PPARy chimera. The PPARy chimera responded to 15-deoxy-A12s 14-PGJn at concentrations as low as 100 nM and with an EC0 of 2 uM (Figure 28 Figure  4A ; Table  1 ). As expected, the thiazolidinedione BRL49653
was the most potent compound in the assay, inducing lipogenesis 1 a-fold at 1 x 1 Oe5 M with an EC& of approximately 90 nM ( Figure  4A ; Table  1 ). Lipogenesis in C3HlOT1/2 cells was stimulated to a lesser degree by treatment with PGD,, A'*-PGJ,, and PGJ2 ( Figure  4A ). in human and monkey urine in significant quantities (-150 ng124 hr in human males) (Hirata et al., 1988) . Higher amounts of other, uncharacterized
A"-PGJ2 immunoreactive compounds have also been detected in human urine (Hirata et al., 1988) . Several groups have examined the levels of PGDz formed from endogenous arachidonic acid in homogenates from various tissues. In two studies, PGD* was found to be most abundant in extracts prepared from rat spleen, with concentrations of IO-30 ,uM reported (Chiabrando et al., 1984; Ujihara et al., 1988) . PGD2 synthetase, the enzyme responsible for PGDz formation, was likewise found to be most abundant in spleen as determined by both enzymatic activity in tissue homogenates and immunohistochemistry (Ujiharaet al., 1988; Urade et al., 1989) . Interestingly, PPARy was recently shown by in situ hybridization analysis to be abundantly expressed in both the red and the white pulp of the rat spleen, indicating a potential role in energy metabolism in the immunesystem (Braissant et al., 1996) . PPARa is also expressed in the red and white pulpof the rat spleen, albeit at lower levels (Braissant et al., 1996) . The colocalization of PPARa and PPARy with PGD, synthetase activity in spleen suggests that PGD2 metabolites may serve as PPAR ligands in this tissue.
PGD* synthetase activity has also been demonstrated in intestine, lung, and liver, tissues in which PPARa, PPARy, or both are expressed (Chiabrando et al., 1984; Ujihara et al., 1988; Urade et al., 1989; lsseman and Green, 1990; Kliewer et al., 1994; Tontonoz et al., 1994a; Braissant et al., 1996) . Thus, PGD2 metabolites may serve as physiologic PPAR ligands in these tissues.
A Potential Role for PGD2 Metabolites in Adipocyte Differentiation PPARy is selectively expressed in adipocytes and was recently shown to play a pivotal role in adipocyte differentiation (Chawla et al., 1994; Tontonoz et al., 1994a Tontonoz et al., , 1994b Lehmann et al., 1995) . Our demonstration that 15deoxy-A", 14-PGJ2 is a PPARy ligand and efficiently promotes differentiation of C3Hl OT112 fibroblasts to adipocytes raises the interesting possibility that this PG serves as an adipogenic signaling molecule in vivo. Several PGs, including PGEz and prostacyclin, are known to be synthesized by isolated adipocytes as well as adipogenic cell lines and to exert marked effects on adipocyte differentiation (Christ and Nugteren, 1970; Axelrod and Levine, 1981) . Furthermore, phospholipase AP levels increase during the course of adipocyte differentiation, suggesting the potential for increased production of cyclooxygenase products (Gao and Serrero, 1990) . Finally, abnormal PG synthesis has been reported in adipocytes isolated from obese Zucker rats (Gaskins et al., 1989) . These results point to an important role for PGs in adipose tissue development and function.
Synthesis of PGD2 has been reported to be low in homogenates prepared from rat epididymal fat relative to other tissues (Ujihara et al., 1988) . It remains possible that PGD2 and its PGJ2 metabolites are present at higher concentrations either locally or transiently during the course of adipocyte differentiation in the epididymal depot.
However, PGD, has been shown to be the major PG synthesized in rat bone marrow homogenates (Kojima et al., 1980; Ujihara et al., 1988) . Bone marrow represents a highly active site for the recruitment of stromal cells to the adipocyte lineage as well as a site of abundant PPARy expression (Greene et al., 1995) . Thus, PGD, metabolites such as 15-deoxy-A '*, 14-PGJ2 may serve as adipogenic signaling agents in the context of bone marrow.
Evidence for a Novel PG Signaling Pathway The previous observations that PPARs are activated by high concentrations of fatty acids, regulate a battery of genes involved in lipid homeostasis, and play a crucial role in adipocyte differentiation suggested that the physiologic ligands for these receptors might be fatty acid metabolites. Our demonstration that the arachidonic acid derivative 15-deoxy-Ai*, "'-PGJ2 binds PPARy supports this hypothesis. Nonetheless, the finding that a PG can serve as a ligand for a nuclear receptor is surprising in that most PGs are known to exert their effects on gene expression through interactions with cell surface receptors, inducing changes in the levels of second messengers. Our data indicate that the PGJ, series of PGs may bypass this second messenger signaling cascade and instead modulate the transcription of target genes directly through interactions with the PPAR family of ligand-activated transcription factors. Our results suggest the existence of a novel PG signaling pathway and, furthermore, raise the intriguing possibility that other eicosanoids may serve as ligands for additional orphan members of the nuclear receptor superfamily.
Experimental Procedures

Chemicals
All PGs were purchased from Cayman Chemical Company (Ann Arbor, Ml).
Cotransfection Assay
The pSG&GAL4-PPARa, pSG5GAL4-NUCl , and pSG5-GAL4PPARy chimeric receptor expression plasmids and (UAS)5-tk-CAT reporter plasmid were previously described (Lehmann et al., 1995) . Transient cotransfection assays using the GAL4-PPAR chimeras were performed as previously described (Lehmann et al., 1995) .
Ligand Binding Assays
To generate histidine-tagged PPARy ligand-binding domain protein, cDNA encoding the entire human PPARy ligand-binding domain (amino acids 176-477) (Greene et al., 1995) was amplified by PCR and inserted into the Ndel-BamHI sitesof bacterial expression plasmid PET-16b (Novagen).
The His-PPARy ligand-binding domain protein was expressed in BL21(DE3)plysS cells and bacterial extracts prepared by freeze-thawing of the cells in lysis buffer containing 10 mM Tris (pH 8.0) 50 mM KCI, 10 mM DTT, and 1% Triton X-100 followed by centrifugation at 40,000 x g for 30 min. For competition binding assays, bacterial extracts (approximately 100 pg of protein) were incubated at 4OC for 2-3 hr with 10 nM PHlBRL49653 (specific activity, 40 CVmmol) in the absence or presence of unlabeled competitor in buffer containing 10 mM Tris (pH 8.0), 50 mM KCI, 10 mM DTT. Bound wasseparatedfromfreeradioactivitybyelution through 1 ml Sephadex G-25 desalting columns (Boehringer Mannheim). Bound radioactivity eluted inthecolumnvoidvolumeandwasquantitated byliquidscintillation counting.
Adipocyte
Differentiation Assays C3Hl OT112 clone 8 murine fibroblasts (American Type Culture Collection) were maintained in Dulbecco's modified Eagle's medium (GIBCO,
